GlassScriptPhysician profile
Amanda Goddard
NPI 1245878107
$2,863.72
in general payments reported to CMS, 2019-2025
30 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2022: $108 · 2023: $578 · 2024: $1,597 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,802 · Long Term Medical Supply Or Device Loan: $665 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,801.62 |
| Long Term Medical Supply Or Device Loan | $665.16 |
| Education | $152.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,051.97 | 2022-2025 | |
| Incyte Corporation | $329.75 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $262.81 | 2023-2025 | Calquence, Fasenra, Onglyza |
| Daiichi Sankyo INC. | $187.26 | 2022-2025 | Enhertu, Injectafer |
| Tersera Therapeutics LLC | $112.61 | 2023-2025 | Zoladex |
| Janssen Biotech, INC. | $71.29 | 2024-2025 | Talvey |
| Lilly USA, LLC | $70.46 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $64.71 | 2023 | Epkinly, Imbruvica |
| Astellas Pharma US INC | $62.10 | 2023-2025 | Padcev, Vyloy, Xtandi |
| Mirati Therapeutics, INC. | $54.27 | 2023-2024 | Krazati |
| Genentech USA, INC. | $50.56 | 2023-2024 | Lunsumio, Venclexta, Gazyva |
| Pfizer INC. | $49.59 | 2025 | |
| Servier Pharmaceuticals LLC | $45.26 | 2024-2025 | |
| Eisai INC. | $43.32 | 2024-2025 | |
| Exelixis INC. | $41.98 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $37.46 | 2024 | Xarelto |
| Pharmaessentia USA Corporation | $34.85 | 2024 | Besremi |
| Amgen INC. | $33.24 | 2023 | Blincyto, Kyprolis |
| Alexion Pharmaceuticals, INC. | $31.01 | 2024 | Ultomiris |
| Adaptive Biotechnologies Corporation | $27.31 | 2024 | Clonoseq |
| Adc Therapeutics America, INC. | $24.07 | 2025 | |
| Array Biopharma INC | $23.79 | 2024 | Braftovi, Tukysa, Mektovi |
| Myriad Genetic Laboratories, INC. | $23.50 | 2023 | Precisetumor |
| Beigene USA, INC. | $22.08 | 2024 | Brukinsa |
| Novocure INC. | $21.17 | 2024 | Optune |
| Genzyme Corporation | $19.91 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.73 | 2021 | |
| Acrotech Biopharma INC. | $18.04 | 2024 | Beleodaq |
| Takeda Pharmaceuticals U.S.A., INC. | $16.75 | 2024 | Iclusig |
| Rigel Pharmaceuticals, INC. | $12.87 | 2024 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Goddard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.